CSPC Pharmaceutical Group Limited (FRA:CVG)
Germany · Delayed Price · Currency is EUR 1.114
+0.004 (0.32%)
At close: Jan 29, 2026
CSPC Pharmaceutical Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 4,328 | 5,873 | 6,091 | 5,605 | 5,160 |
Depreciation & Amortization | 1,249 | 1,083 | 1,004 | 862.38 | 804.45 |
Other Amortization | 90.65 | 34.94 | 43.45 | 3.1 | 4.36 |
Loss (Gain) From Sale of Assets | 23.4 | 22.23 | 7.36 | 10.79 | -285.28 |
Asset Writedown & Restructuring Costs | 0.18 | 42.32 | 72.11 | 50 | - |
Loss (Gain) From Sale of Investments | 151.94 | 177.85 | -148.97 | -242.41 | -568.29 |
Loss (Gain) on Equity Investments | 89.47 | 54.2 | 15.4 | -22.44 | -13.53 |
Stock-Based Compensation | 210.45 | 235.09 | 160.73 | 17.73 | 9.13 |
Provision & Write-off of Bad Debts | 16.3 | 18.41 | -25.73 | 4.07 | 9.69 |
Other Operating Activities | -807.3 | -330.26 | -391.27 | -263.85 | -60.75 |
Change in Accounts Receivable | 692.25 | -1,973 | -566.55 | -943.55 | -445.45 |
Change in Inventory | 8.65 | -583.75 | -42.75 | -617.07 | 601.44 |
Change in Accounts Payable | -758.87 | 918.13 | 18.45 | 276.79 | 337.71 |
Change in Unearned Revenue | 135.12 | -275.07 | 468.63 | -44.22 | 291.57 |
Change in Other Net Operating Assets | -894.41 | -1,118 | 920.34 | -59.87 | 894.92 |
Operating Cash Flow | 4,535 | 4,179 | 7,627 | 4,637 | 6,740 |
Operating Cash Flow Growth | 8.52% | -45.21% | 64.50% | -31.20% | 78.11% |
Capital Expenditures | -2,015 | -1,624 | -2,220 | -1,410 | -1,356 |
Sale of Property, Plant & Equipment | 99.92 | 139.99 | 16.83 | 85.69 | 28.83 |
Cash Acquisitions | - | - | -341.91 | -24.35 | -18.13 |
Divestitures | - | - | - | 150.91 | -302.42 |
Sale (Purchase) of Intangibles | -560.08 | -265.43 | -484.54 | -339.15 | -21.49 |
Investment in Securities | -1,615 | 2,171 | -4,075 | 630.71 | -450.06 |
Other Investing Activities | 232.62 | 443.5 | 308.74 | 269.01 | -10.01 |
Investing Cash Flow | -3,858 | 865.86 | -6,796 | -637.33 | -2,130 |
Short-Term Debt Issued | - | - | - | - | 169 |
Long-Term Debt Issued | 28 | - | 485.71 | - | - |
Total Debt Issued | 28 | - | 485.71 | - | 169 |
Long-Term Debt Repaid | -152.36 | -166.43 | -620.95 | -222.17 | -92.32 |
Total Debt Repaid | -152.36 | -166.43 | -620.95 | -222.17 | -92.32 |
Net Debt Issued (Repaid) | -124.36 | -166.43 | -135.24 | -222.17 | 76.68 |
Issuance of Common Stock | 106.43 | - | - | - | - |
Repurchase of Common Stock | -2,196 | -458.95 | -14.21 | -263.51 | - |
Common Dividends Paid | -3,234 | -2,726 | -2,097 | -1,691 | -1,528 |
Other Financing Activities | 194 | 792.06 | 342.34 | -20.16 | -19.96 |
Financing Cash Flow | -5,253 | -2,560 | -1,904 | -2,197 | -1,471 |
Foreign Exchange Rate Adjustments | 3.4 | 4.89 | 14.14 | -2.44 | 2.1 |
Net Cash Flow | -4,573 | 2,490 | -1,059 | 1,800 | 3,141 |
Free Cash Flow | 2,519 | 2,555 | 5,407 | 3,226 | 5,383 |
Free Cash Flow Growth | -1.40% | -52.74% | 67.58% | -40.07% | 183.19% |
Free Cash Flow Margin | 8.69% | 8.12% | 17.48% | 11.58% | 21.58% |
Free Cash Flow Per Share | 0.21 | 0.21 | 0.45 | 0.27 | 0.45 |
Cash Interest Paid | 7.65 | 15.99 | 21.54 | 7.66 | 12.23 |
Cash Income Tax Paid | 1,693 | 1,309 | 1,335 | 1,141 | 1,061 |
Levered Free Cash Flow | 2,130 | 1,164 | 3,826 | 1,721 | 4,120 |
Unlevered Free Cash Flow | 2,158 | 1,180 | 3,841 | 1,726 | 4,128 |
Change in Working Capital | -817.26 | -3,032 | 798.12 | -1,388 | 1,680 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.